News: CTE Cryosite Says Outlook Remains Positive, page-4

Interesting how yesterday was the first ever Corporate Presentation they have ever done going back last 2 years - since 2022. Nothing says to instos to "Look at us please!" by having a nice little slide show.

Clinical Trials and Biological Services have been the ONLY driver of growth.
Cord Blood and Storage has actually been DECLINING contributor from $1.4M in 2018 to $1.1M in 2023.

They said they have been heavily investing in CapEx the past few years - was it for Trials and Services or Storage?
Clearly their focus should be on the former rather than latter.

Was the high CapEx the reason for the 2 big dips in SP in 2010 and 2018?

If Lindemark bought 1M shares at 83c on 23 April off market trade then who bought 1M at 85c on 05 May on a crossed block trade?

The only way to drive the SP higher is if CTE gets more insto involvement. With retail holding just over a third at 34.4% or 16.8M shares of total 48.8M and directors and other majority holders account for the rest, How will Instos get on board?